8-M-PDOT - CAS 134865-70-6
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C14H19NO2
Molecular Weight:
233.31
COA:
Inquire
Targets:
Melatonin Receptor
Description:
8-M-PDOT is a melatonin receptor agonist, with 20-fold selective for the MT2 (vs MT1) subtype (pKi = 8.23 and 8.95 at human recombinant MT1 and MT2 receptors respectively).
Purity:
≥99% by HPLC
Appearance:
White solid
Synonyms:
8-Methoxy-2-propionamidotetralin
Solubility:
Ethanol to 50 mM; DMSO to 100 mM
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
InChIKey:
RVIGBTUDFAGRTQ-UHFFFAOYSA-N
InChI:
InChI=1S/C14H19NO2/c1-3-14(16)15-11-8-7-10-5-4-6-13(17-2)12(10)9-11/h4-6,11H,3,7-9H2,1-2H3,(H,15,16)
Canonical SMILES:
CCC(=O)NC1CCC2=C(C1)C(=CC=C2)OC
1.Melatonin Suppresses Neuropathic Pain via MT2-Dependent and -Independent Pathways in Dorsal Root Ganglia Neurons of Mice.
Lin JJ;Lin Y;Zhao TZ;Zhang CK;Zhang T;Chen XL;Ding JQ;Chang T;Zhang Z;Sun C;Zhao DD;Zhu JL;Li ZY;Li JL Theranostics. 2017 May 12;7(7):2015-2032. doi: 10.7150/thno.19500. eCollection 2017.
Melatonin (Mel) and its receptors (MT1 and MT2) have a well-documented efficacy in treating different pain conditions. However, the anti-nociceptive effects of Mel and Mel receptors in neuropathic pain (NP) are poorly understood. To elucidate this process, pain behaviors were measured in a dorsal root ganglia (DRG)-friendly sciatic nerve cuffing model. We detected up-regulation of MT2 expression in the DRGs of cuff-implanted mice and its activation by the agonist 8-M-PDOT (8MP). Also, Mel attenuated the mechanical and thermal allodynia induced by cuff implantation. Immunohistochemical analysis demonstrated the expression of MT2 in the DRG neurons, while MT1 was expressed in the satellite cells. In cultured primary neurons, microarray analysis and gene knockdown experiments demonstrated that MT2 activation by 8MP or Mel suppressed calcium signaling pathways via MAPK1, which were blocked by RAR-related orphan receptor alpha (RORα) activation with a high dose of Mel. Furthermore, expression of nitric oxide synthase 1 (NOS1) was down-regulated upon Mel treatment regardless of MT2 or RORα. Application of Mel or 8MP in cuff-implanted models inhibited the activation of peptidergic neurons and neuro-inflammation in the DRGs by down-regulating ;c-fos;, calcitonin gene-related peptide [CGRP], and tumor necrosis factor-1α [TNF-1α] and interleukin-1β [IL-1β].
2.REM sleep deprivation promotes a dopaminergic influence in the striatal MT2 anxiolytic-like effects.
Noseda AC;Targa AD;Rodrigues LS;Aurich MF;Lima MM Sleep Sci. 2016 Jan-Mar;9(1):47-54. doi: 10.1016/j.slsci.2015.10.002. Epub 2015 Nov 10.
The aim of this study was to investigate the possible anxiolytic-like effects of striatal MT2 activation, and its counteraction induced by the selective blockade of this receptor. Furthermore, we analyzed this condition under the paradigm of rapid eye movement (REM) sleep deprivation (REMSD) and the animal model of Parkinson's disease (PD) induced by rotenone. Male Wistar rats were infused with intranigral rotenone (12 μg/μL), and 7 days later were subjected to 24 h of REMSD. Afterwards the rats underwent striatal micro-infusions of selective melatonin MT2 receptor agonist, 8-M-PDOT (10 μg/μL) or selective melatonin MT2 receptor antagonist, 4-P-PDOT (5 μg/μL) or vehicle. Subsequently, the animals were tested in the open-field (OP) and elevated plus maze (EPM) tests. Results indicated that the activation of MT2 receptors produced anxiolytic-like effects. In opposite, the MT2 blockade did not show an anxiogenic-like effect. Besides, REMSD induced anxiolytic-like effects similar to 8-M-PDOT. MT2 activation generated a prevalent locomotor increase compared to MT2 blockade in the context of REMSD. Together, these results suggest a striatal MT2 modulation associated to the REMSD-induced dopaminergic supersensitivity causing a possible dopaminergic influence in the MT2 anxiolytic-like effects in the intranigral rotenone model of PD.
3.MT2-like melatonin receptor modulates amplitude receptor potential in visual cells of crayfish during a 24-hour cycle.
Mendoza-Vargas L;Solís-Chagoyán H;Benítez-King G;Fuentes-Pardo B Comp Biochem Physiol A Mol Integr Physiol. 2009 Dec;154(4):486-92. doi: 10.1016/j.cbpa.2009.07.025. Epub 2009 Aug 8.
Retinular photoreceptors are structures involved in the expression and synchronization of the circadian rhythm of sensitivity to light in crayfish. To determine whether melatonin possesses a differential effect upon the receptor potential (RP) amplitude of retinular photoreceptors circadian time (CT)-dependent, we conducted experiments by means of applying melatonin every 2h during a 24-hour cycle. Melatonin with 100 nM increased RP amplitude during subjective day to a greater degree than during subjective night. To determine whether MT(2) melatonin receptors regulate the melatonin-produced effect, we carried out two experiments, circadian times (CTs) 6 and 18, which included the following: (1) application of the MT(2) receptor selective agonist 8-M-PDOT and antagonist DH97, and (2) the specific binding of [(125)I]-melatonin in eyestalk membranes. The amount of 10 nM of 8-M-PDOT increased RP amplitude in a similar manner to melatonin, and 1 nM DH97 abolished the increase produced by melatonin and 8-M-PDOT. Binding of [(125)I]-melatonin was saturable and specific. Scatchard analysis revealed an affinity constant (K(d)) of 1.1 nM and a total number of binding sites (B(max)) of 6 fmol/mg protein at CT 6, and a K(d) of 1.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Melatonin Receptor Products


CAS 220339-00-4 DH 97

DH 97
(CAS: 220339-00-4)

DH 97 is a potent MT2 melatonin receptor antagonist (pKi = 8.03) with 89- and 229-fold selectivity over MT1 and GPR50 (melatonin-related orphan receptor) respec...

LY 156735
(CAS: 118702-11-7)

This active molecular is high affinity nonselective melatonin receptors MT1 and MT2 agonist which is under development for the treatment of insomnia and other s...

CAS 63762-74-3 6-Chloromelatonin

6-Chloromelatonin
(CAS: 63762-74-3)

6-Chloromelatonin is a potent agonist of the melatonin receptors, which is active at nanomolar concentrations. It shows higher affinity for binding to hamster b...

CAS 609799-22-6 Tasimelteon

Tasimelteon
(CAS: 609799-22-6)

Tasimelteon (trade name Hetlioz) is a drug approved by the FDA solely for the treatment of non-24-hour sleep–wake disorder (often designated as N24HSWD) in tota...

CAS 343263-95-6 DH 97

DH 97
(CAS: 343263-95-6)

DH 97 is a selective MEL-1B-R (melatonin receptor) antagonist.

CAS 190277-13-5 GR 135531

GR 135531
(CAS: 190277-13-5)

GR 135531 is a high affinity agonist of MT3 melatonin receptors, with low affinity for MT1 and MT2 melatonin receptors. GR 135531 can be used to discriminate be...

CAS 80270-68-4 AH 001

AH 001
(CAS: 80270-68-4)

AH 001 is a potent melatonin agonist.

CAS 196597-26-9 Ramelteon

Ramelteon
(CAS: 196597-26-9)

Ramelteon has high affinity with recombinant human MT1 and MT2 receptors with pKi of 10.05 and 9.70, respectively.

Chemical Structure

CAS 134865-70-6 8-M-PDOT

Quick Inquiry

Verification code

Featured Items